PREVALENCE OF DRUG-TREATED DIABETES-MELLITUS IN BELGIUM - RESULTS OF A STUDY WITH THE COLLABORATION OF A NETWORK OF PHARMACIES

被引:6
作者
WALCKIERS, D [1 ]
VANDERVEKEN, J [1 ]
PAPOZ, L [1 ]
STROOBANT, A [1 ]
机构
[1] WHO,COLLABORATING CTR CLIN RES & DIABET EPIDEMIOL,INSERM,U21,UNITE RECH CLIN & EPIDEMIOL,VILLEJUIF,FRANCE
关键词
DIABETES-MELLITUS; BELGIUM; EPIDEMIOLOGY; PREVALENCE; ANTIDIABETIC DRUGS; PHARMACISTS;
D O I
10.1007/BF02284959
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Within the framework of a European concerted action on diabetes mellitus (EURODIAB SubArea C), an epidemiological study was established in Belgium in 1990 in order to estimate the prevalence of drug-treated diabetes mellitus. An assessment was made of the sales of insulin and oral antidiabetic drugs and the average daily dose used. A sample of people with diabetes, clients of 107 pharmacies, provided the data to establish average daily doses. Those pharmacies, spread over the 9 provinces of the country, represent 2% of all private pharmacies in Belgium. Over a 2 month period each pharmacist presented a questionnaire to each client receiving an anti-diabetic drug. In 1990, 164 per 10,000 inhabitants were treated with antidiabetic drugs, which means that there were approximately 163,000 drug-treated diabetics in Belgium. At the time of the survey 65% of the diabetics in the sample were 60 years or older. Overall, 38% of drug-treated diabetics took insulin, and 30% of them took only human insulin. Treatment type varied by the province where the pharmacy was located. The provinces of Hainaut and Luxembourg-Namur had a higher percentage of diabetics on oral treatment. This is the first description in Belgium of the prevalence of drug-treated diabetes and of the pattern of prescribing of these drugs.
引用
收藏
页码:613 / 619
页数:7
相关论文
共 17 条
[2]   MEASUREMENT OF DRUG CONSUMPTION - DRUGS FOR DIABETES IN NORTHERN-IRELAND, NORWAY AND SWEDEN [J].
BERGMAN, U ;
ELMES, P ;
HALSE, M ;
HALVORSEN, T ;
HOOD, H ;
LUNDE, PKM ;
SJOQVIST, F ;
WADE, OL ;
WESTERHOLM, B .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1975, 8 (02) :83-89
[3]  
CALLEPASCUAL AL, 1988, MED CLIN-BARCELONA, V1, P40
[4]  
Dean A. G., 1990, EPI INFO VERSION 5 W
[5]  
FONTBONNE A, 1986, REV EPIDEMIOL SANTE, V34, P100
[6]  
FONTBONNE A, 1985, THESIS U PARIS SUD
[7]  
FULLER JH, 1989, DIABETIC MED, V6, P278
[8]  
Gallagher D.L., 1988, ADV SPACE RES, V8, P15, DOI [10.1016/0273-1177(88)90258-X, DOI 10.1016/0273-1177(88)90258-X]
[9]  
HORTULANUSBECK D, 1990, DIABETES METAB, V16, P311
[10]   PATTERN OF TREATMENT AMONG DIABETIC-PATIENTS IN FRANCE [J].
PAPOZ, L ;
VAUZELLE, F ;
VEXIAU, P ;
CATHELINEAU, G .
DIABETES CARE, 1988, 11 (07) :586-591